
(Healthday News) — The U.S. Food and Drug Administration’s controversial approval of a new Alzheimer’s drug, along with its high price, is now being investigated by two House committees. “We have serious concerns about the steep price of Biogen’s new Alzheimer’s drug Aduhelm and the process that led to its approval despite questions about the… read on > read on >